Used in cancer research and therapy development due to its ability to block vascular endothelial growth factor receptor 2 (VEGFR2), a key protein involved in tumor angiogenesis. By inhibiting VEGFR2 signaling, this reference antibody helps prevent the formation of new blood vessels that supply nutrients to tumors, thereby restricting tumor growth and metastasis. It serves as a critical tool for validating anti-angiogenic drugs and developing biosimilars or next-generation antibodies targeting the VEGF pathway. Commonly used in preclinical studies, immunoassays, and as a benchmark in therapeutic antibody characterization.